Beneficial effects of a novel thyromimetic on lipoprotein metabolism

Molecular Pharmacology

Volumn 52, Issue 3, 1997, Pages 542-547

  Taylor, Anthony H ^a   Stephan, Zouhair F ^b   Steele, Ronald E ^b   Wong, Norman C W ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

3,5 DIBROMO 3' (2,3 DIHYDRO 3 OXO 6 PYRIDAZINYLMETHYL)THYRONINE; APOLIPOPROTEIN A; CGS 23425; CGS 26214; THYROID HORMONE; THYROMIMETIC AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BINDING AFFINITY; CARDIOTOXICITY; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; ENZYME ACTIVITY; FEEDING BEHAVIOR; HEART ATRIUM CONTRACTILITY; HYPERCHOLESTEROLEMIA; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0030845720     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.52.3.542     Document Type: Article

References (36)

1. Franklyn, J. A., J. Daykin, J. Betteridge, E. A. Hughes, R. Holder, S. R. Jones, and M. C. Sheppard. Thyroxine replacement therapy and circulating lipid concentrations. Clin. Endocrinol. 38:453-459 (1993).
2. Packard, C. J., J. Shepherd, G. M. Lindsay, A. Gaw, and M. R. Taskinen. Thyroid replacement therapy and its influence on postheparin plasma lipases and apolipoprotein-B metabolism in hypothyroidism. J. Clin. Endocrinol. Metab. 76:1209-1216 (1993).
3. Scarabottolo, L., E. Trezzi, P. Roma, and A. L. Catapano. Experimental hypothyroidism modulates the expression of the low density lipoprotein receptor by the liver. Atherosclerosis 59:329-333 (1986).
4. Severson, D. L., and T. Fletcher. Effect of thyroid hormones on acid cholesterol ester hydrolase activity in the rat liver, heart and epididymal fat pads. Biochim. Biophys. Acta 675:256-264 (1981).
5. Ridgway, N. D., and P. J. Dolphin. Serum activity and hepatic secretion of lecithin:cholesterol acyltransferase in experimental hypothyroidism and hypercholesterolemia. J. Lipid Res. 26:1300-1313 (1985).
6. Hulsmann, W. C., M. C. Oerlemans, and M. M. Geelhoed-Mieras. Effect of hypothyroidism, diabetes and polyunsaturated fatty acids on heparin-releasable rat liver lipase. Biochem. Biophys. Res. Commun. 79:784-788 (1977).
7. The Coronary Drug Project Research Group. The Coronary drug project. Findings leading to further modifications of its protocol with respect to dextrothyroxine. J. Am. Med. Assoc. 220:996-1008 (1972).
8. 3 enantiomers. Endocrinology 113:1236-1243 (1983).
9. Lakshmanan, M., E. Goncalves, A. Pontecorvi, and J. Robbins. Differential effect of a new thyromimetic on triiodothyronine transport into myoblasts and hepatoma and neuroblastoma cells. Biochim. Biophys. Acta 1133:213-217 (1992).
10. Barlow, J. W., L. E. Raggatt, C. F. Lim, E. Kolliniatis, D. J. Topliss, and J. R. Stockigt. The thyroid hormone analogue SKF-94901 and iodothyronine binding sites in mammalian tissues: differences in cytoplasmic binding between liver and heart. Acta Endocrinol. 124:37-44 (1991).
11. Emmelot, P., C. J. Bos, R. P. Van Hoeven, and W. J. Van Blitterswijk. Isolation of plasma membranes from rat and mouse livers and hepatomas. Methods Enzymol. 31:75-90 (1974).
12. Spindler, B. J., K. M. MacLeod, J. Ring, and J. D. Baxter. Thyroid hormone receptors. Binding characteristics and lack of hormonal dependency for nuclear localization. J. Biol. Chem. 250:4113-4119 (1975).
13. Stephan, Z. F., E. C. Yurachek, R. Sharif, J. M. Wasvary, K. S. Leonards, C.-W. Hu, T. H. Hintze, and R. E. Steele. Demonstration of potent lipid-lowering activity by a thyromimetic agent devoid of cardiovascular and thermogenic effects. Atherosclerosis 126:53-63 (1996).
14. Pliam, N. B., and I. D. Goldfine. High affinity thyroid hormone binding sites on purified rat liver plasma membranes. Biochem. Biophys. Res. Commun. 79:166-172 (1977).
15. Taylor, A. H., J. Raymond, J. M. Dionne, J. Romney, D. E. Lawless, J. Chan, I. E. Wanke, N. C. W. Wong. Glucocorticoid increases rat apolipoprotein A-I promoter activity. J. Lipid Res. 37:2232-2243 (1996).
16. Murayama, M., and M. J. Goodkind. Effect of thyroid hormone on the frequency-force relationship of atrial myocardium from the guinea pig. Circ. Res. 23:743-751 (1968).
17. Taylor, A. H., P. Wishart, D. E. Lawless, J. Raymond, and N. C. W. Wong. Identification of functional positive and negative thyroid hormone-responsive elements in the rat apolipoprotein AI promoter. Biochemistry 35:8281-8288 (1996).
18. Segal, J., J. Hardiman, and S. H. Ingbar. Stimulation of calcium-ATPase activity by 3,5,3′-tri-iodothyronine in rat thymocyte plasma membranes. A possible role in the modulation of cellular calcium concentration. Biochem. J. 261:749-754 (1989).
19. Yokoyama, N., G. N. Walker, A. J. Main, J. L. Stanton, M. M. Morrissey, C. Boehm, A. Engle, A. D. Neubert, J. M. Wasvary, Z. F. Stephan, and R. E. Steele. Synthesis and structure activity relationships of oxamic acid and acetic acid derivatives related to L-thyronine. J. Med. Chem. 38:695-707 (1995).
20. Bedotto, J. B., R. G. Gay, S. D. Graham, E. Morkin, and S. Goldman. Cardiac hypertrophy induced by thyroid hormone is independent of loading conditions and beta adrenoceptor blockade. J. Pharmacol. Exp. Ther. 248:632-636 (1989).
21. Steele, R. E., J. M. Wasvary, B. N. Dardik, C. D. Schwartzkopf, R. Sharif, K. S. Leonards, C. W. Hu, E. C. Yurachek, and Z. F. Stephan. CGS 26214, the thyroxine connection revisited. Atherosclerosis 10:321-324 (1995).
22. Ellis, D., J. C. Emmett, S. B. Flynn, P. Leeson, and A. H. Underwood. SK&F L-94901-. A novel selective thyromimetic with potent hypocholesterolaemic activity. Br. J. Pharmacol. 89(suppl.):829P (1986).
23. 3 by liver targeting with cholic acid. Biochem. Pharmacol. 43: 1969-1974 (1992).
24. Underwood, A. H., J. C. Emmett, D. Ellis, S. B. Flynn, P. D. Leeson, G. M. Benson, R. Novelli, N. J. Pearce, and V. P. Shah. A thyromimetic that decreases plasma cholesterol levels without increasing cardiac activity. Nature (Lond.) 324:425-429 (1986).
25. Babiak, J., and L. L. Rudel. Lipoproteins and atherosclerosis. Bailliere's Clin. Endocrinol. Metab. 1:515-550 (1987).
26. Barboriak, J. J. Alcohol, lipids and heart disease. Alcohol 1:341-345 (1984).
27. Chait, A., E. L. Bierman, and J. J. Albers. Regulatory role of triiodothyronine in the degradation of low density lipoprotein by cultured human skin fibroblasts. J. Clin. Endocrinol. Metab. 48:887-889 (1979).
28. Thompson, G. R., A. K. Soutar, F. A. Spengel, A. Jadhav, S. J. Gavigan, and N. B. Myant. Defects of receptor-mediated low density lipoprotein catabolism in homozygous familial hypercholesterolemia and hypothyroidism in vivo. Proc. Natl. Acad. Sci. USA 78:2591-2595 (1981).
29. Jorgensen, E. C. Thyroid hormones and analogs. II. Structure-activity relationships, in Hormonal Proteins and Peptides, Vol. VI. Thyroid Hormones (Li, C. H., ed.). Academic Press, New York, 108-204 (1973).
30. Richards, T., H. Horlock, and P. Gallagher. Atherosclerosis in modified WHHL rabbits. Anim. Technol. 37:1-6 (1986).
31. Rubin, E. M., R. M. Krauss, E. A. Spangler, J. G. Verstuyft, and S. M. Clift. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature (Lond.) 353:265-267 (1991).
32. Strobl, W., L. Chan, and W. Patsch. Differential regulation of hepatic apolipoprotein A-I and A-II gene expression by thyroid hormone in rat liver. Atherosclerosis 97:161-170 (1992).
33. Commuzie, A. G., J. Bangero, M. C. Mahoney, R. M. Sharp, J. L. Van de Berg, M. P. Sterm, and J. W. MacCluer. Triiodothyronine exerts a major pleiotropic effect on reverse cholesterol transport phenotypes. Arterioscler. Thromb. Vasc. Biol. 16:289-293 (1996).
34. Takeda, T., S. Suzuki, R. T. Liu, and L. J. DeGroot. Triiodothyroacetic acid has unique potential for therapy of resistance to thyroid hormone. J. Clin. Endocrinol. Metab. 80:2033-2040 (1995).
35. Falcone, M., T. Miyamato, F. Fierro-Renoy, E. Macchia, and L. J. DeGroot. Antipeptide polyclonal antibodies specifically recognize each human thyroid hormone receptor isoform. Endocrinology 131:2419-2429 (1992).
36. Sakurai, A., A. Nakai, and L. J. DeGroot. Expression of three forms of thyroid hormone receptor in human tissues. Mol. Endocrinol. 3:392-399 (1989).